Company Analysis TG Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (65.68%) is higher than the sector average (-43.68%).
Disadvantages
- Price (29.21 $) is higher than fair price (1.14 $)
- Dividends (0%) are below the sector average (0.5399%).
- Current debt level 33.62% has increased over 5 years from 25.03%.
- The company's current efficiency (ROE=7.9%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| TG Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.8% | -25.1% | -4.9% |
| 90 days | -16.5% | -45.3% | 0.1% |
| 1 year | 65.7% | -43.7% | 19.4% |
TGTX vs Sector: TG Therapeutics, Inc. has outperformed the "Healthcare" sector by 109.36% over the past year.
TGTX vs Market: TG Therapeutics, Inc. has outperformed the market by 46.25% over the past year.
Stable price: TGTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: TGTX with weekly volatility of 1.26% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (29.21 $) is higher than the fair price (1.14 $).
Price is higher than fair: The current price (29.21 $) is 96.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (368.52) is higher than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (368.52) is higher than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (29.1) is higher than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (29.1) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (19.99) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (19.99) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (179.61) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (179.61) is higher than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20.91% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20.91%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (7.9%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (7.9%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (3.84%) is higher than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (3.84%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-86.89%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-86.89%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
